Altshuler Shaham Ltd Makes New $482,000 Investment in Sanofi (NASDAQ:SNY)

Altshuler Shaham Ltd acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,000 shares of the company's stock, valued at approximately $482,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. increased its stake in shares of Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after acquiring an additional 408,752 shares in the last quarter. Boston Partners boosted its holdings in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after acquiring an additional 2,501,073 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Sanofi by 10.8% during the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after acquiring an additional 369,530 shares in the last quarter. Magnetar Financial LLC raised its position in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. Finally, Natixis Advisors LLC boosted its stake in Sanofi by 1.2% in the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company's stock worth $140,350,000 after purchasing an additional 35,828 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SNY shares. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Price Performance

Shares of Sanofi stock traded up $0.88 during trading on Tuesday, reaching $51.81. 2,185,292 shares of the stock traded hands, compared to its average volume of 2,352,448. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $130.88 billion, a price-to-earnings ratio of 20.85, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The business has a fifty day simple moving average of $54.65 and a two-hundred day simple moving average of $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is currently 64.26%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.